Spero Therapeutics, Inc. (SPRO)
2.175
-0.04
(-1.58%)
USD |
NASDAQ |
Feb 27, 11:30
Spero Therapeutics Research and Development Expense (Quarterly) : 8.597M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 192.41M |
| Amicus Therapeutics, Inc. | 23.74M |
| Cassava Sciences, Inc. | 3.955M |
| Alpha Teknova, Inc. | 0.542M |
| Pyxis Oncology, Inc. | 17.35M |